In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common …
The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …
Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite Therapeutics …
GSK has high hopes for Jemperli as it transitions to what’s being called the “new GSK,” with a greater focus on experimental drugs for infectious …
Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. …
